TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02707757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythopoietin stimulating agent
Description: Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
Study: NCT03550950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64232025 IV
Description: JNJ-64232025 will be administered as IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64232025 SC
Description: JNJ-64232025 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as IV infusion or SC injection.
Study: NCT01716156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
Study: NCT00004148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant vaccinia-B7.1 vaccine
Study: NCT04519515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allergan Vollure
Description: Injection of Allergan Vollure into Atrophic Scars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allergan Vollure
Description: Injection of Allergan Vollure into Atrophic Scars
Study: NCT00271492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: 1 10mg capsule to be taken daily for 6 month study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrasentan
Description: 1 10mg capsule per day for the 6 month study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atrasentan
Description: One 10 mg capsule per day for 6 month study period
Study: NCT01490567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 5mg/d
Study: NCT01942239

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real time continuous glucose monitoring
Study: NCT04165252

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of vaginal, neonatal buccal and placental samples
Description: Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of vaginal, neonatal buccal and placental samples
Description: Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
Study: NCT03616405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
Study: NCT02528279

Intervention type: DRUG
Group type: OTHER
Intervention: Coartem
Description: Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight \> 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food.
Study: NCT01861535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Study: NCT00918645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 41 Ca
Description: single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
Study: NCT03950362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
Study: NCT02010918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulfate /chondroitin sulfate - capsules
Description: 500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulfate /chondroitin sulfate - sachet
Description: 1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cosamin DS®
Description: 500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
Study: NCT03590795

Intervention type: OTHER
Intervention: Sleep survey
Description: The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry \[including Philips\]).
Study: NCT04440436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T Cells
Description: IM19 CAR-T cells~Drug: Fludarabine~Two days before cell infusion, all patients will be treated with fludarabine for 3 days~Drug: Cyclophosphamide~Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
Study: NCT01995162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy expenditure estimation
Description: Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
Study: NCT02222818

Intervention type: DEVICE
Group type: OTHER
Intervention: Conducted AF Response (CAFR)
Description: The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conducted AF Response (CAFR)
Description: The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conducted AF Response Plus (CAFRPlus)
Description: The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.

Intervention type: DEVICE
Group type: OTHER
Intervention: Conducted AF Response Plus (CAFRPlus)
Description: The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
Study: NCT01670890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMZ
Description: patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ plus CDDP
Description: patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
Study: NCT02043132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
Study: NCT01449188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: FDA approved drug used to treat nausea and vomiting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: FDA approved drug used to treat nausea and vomiting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: FDA approved antibiotic commonly used as a positive control in thorough QT studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: USP saline IV solution used as placebo for ondansetron IV.
Study: NCT01528163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
Study: NCT00764712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
Study: NCT03851354

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound meal acommodation test
Description: to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
Study: NCT04413227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Recombinant Human Endostatin（PEG-ENDO）
Description: PEG-ENDO 1 mg/kg or 2 mg/kg or 4 mg/kg or 6 mg/kg or 8 mg/kg+Docetaxel 75 mg/m2，once every 3 weeks at day 1
Study: NCT04279288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherm mask
Description: a cooling mask used to treat localized swelling and bleeding
Study: NCT00540098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine + aerobic exercise
Description: paroxetine, 40 mg once daily + regular aerobic exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine + relaxation
Description: paroxetine, 40 mg once daily + regular relaxation training

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + aerobic exercise
Description: placebo pill once daily + regular aerobic exercise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + relaxation
Description: placebo pill once daily + regular relaxation training
Study: NCT01377285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB
Description: Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Pentoxifylline)
Description: Sugar pill manufactured to mimic Pentoxifylline 400mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Pentoxifylline)
Description: Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
Study: NCT03119701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: Lyophilisate for solution for injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lyophilisate for solution for injection as placebo.
Study: NCT01198171

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02392286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
Study: NCT04247945

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cotransplant with MSCs
Description: Co-transplantation of MSCs during allogeneic HSCT
Study: NCT03488147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20 mg esomeprazole tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: 20 mg esomeprazole tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: resembling esomeprazole tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: resembling esomeprazole tablet
Study: NCT04537481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid extraction
Description: The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid extraction
Description: The sperm samples were used for lipid extraction. Lipids were analyzed using the UPLC-MS system.
Study: NCT03839719

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group PI
Description: Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group OC
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group OC
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group CHX
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group CHX
Description: After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
Study: NCT04378621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF-α inhibitor OR JAK inhibitor
Description: Pharmacological anti-rheumatic treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand training
Description: Physical hand training 10 min twice daily while on stable treatment
Study: NCT01640197

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Methyl Cellulose. 1 capsule taken once daily for 28 days.
Study: NCT03909607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 0.75 mg/kg
Description: Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 1.0 mg/kg
Description: Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
Study: NCT01198171

Intervention type: OTHER
Intervention: Study of Socioeconomic and Demographic Variables
Study: NCT03909607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 1.5 mg/kg
Description: Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
Study: NCT02048293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanyl, Ultiva®
Description: Anesthetic induction for orotracheal intubation. Group O

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanyl, Ultiva®
Description: Anesthetic induction for orotracheal intubation. Group O
Study: NCT04358237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Lurbinectedin will be presented as a lyophilized powder for concentrate for solution for infusion in 4-mg vials. Before use, the 4-mg vial will be reconstituted with 8 mL of sterile water for injection, to give a solution containing 0.5 mg/mL of PM01183. For administration to patients as IV infusion, reconstituted vials will be diluted with glucose 50 mg/mL (5%) or sodium chloride 9 mg/mL (0.9%) solution for infusion.~PM01183 will be administered as a 1 hour IV infusion Q3W, in a minimum volume of 100 mL of solution for infusion (either 5% glucose or 0.9% sodium chloride), or a minimum volume of 250 mL if through a peripheral line, always at a fixed rate and through a pump device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be supplied as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
Study: NCT02220985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT
Study: NCT03550950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as IV infusion or SC injection.